Loading...
Docoh

293 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-99.2
GOVX Geovax Labs Inc
4 Aug 22
GeoVax Reports 2022 Second Quarter Financial Results
4:06pm
for clinical trial materials. The increase is also reflective of higher personnel and consulting costs as we stacked up for an overall higher level
8-K
EX-99.1
GOVX Geovax Labs Inc
4 Aug 22
GeoVax Reports 2022 Second Quarter Financial Results
4:06pm
personnel and consulting costs, costs of manufacturing materials for use in clinical trials, and a generally higher level of activity. General
8-K
GOVX Geovax Labs Inc
4 Aug 22
GeoVax Reports 2022 Second Quarter Financial Results
4:06pm
, supplement or amend the materials attached hereto. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2 and 99.3, shall
424B3
GOVX Geovax Labs Inc
3 Aug 22
Prospectus supplement
4:36pm
”), that manufacture product used in the clinical trials; expenses incurred in procuring materials and for analytical and release testing services required … clinical trials for GEO-CM04S1 and Gedeptin, costs of manufacturing materials for use in our clinical trials, and a generally higher level of activity
424B3
GOVX Geovax Labs Inc
3 Aug 22
Prospectus supplement
4:35pm
”), that manufacture product used in the clinical trials; expenses incurred in procuring materials and for analytical and release testing services required … clinical trials for GEO-CM04S1 and Gedeptin, costs of manufacturing materials for use in our clinical trials, and a generally higher level of activity
424B3
dlkst4avfd0ert4a
3 Aug 22
Prospectus supplement
4:34pm
10-Q
qcoik 0vzc62
3 Aug 22
Quarterly report
4:31pm
10-Q
EX-10.12
w1mizkvp70d 920q
3 Aug 22
Quarterly report
4:31pm
424B3
vvyszorb0y2pjjr5
27 Jun 22
Prospectus supplement
9:13am
D
6nos 15mb
22 Jun 22
$15M in equity / options, sold $15M, 1 investor
4:28pm
S-1
4n7xyt3qwr
14 Jun 22
IPO registration
4:03pm
DEF 14A
qpwv9nsgpm51976 3p
13 Jun 22
Definitive proxy
4:57pm
PRE 14A
n3f5gns hpfum6t2
27 May 22
Preliminary proxy
5:07pm
8-K
EX-10.5
2oj8de9 f8mjzc6j
27 May 22
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
4:48pm
8-K
EX-10.4
16hblmln
27 May 22
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
4:48pm
8-K
EX-10.1
se98fpplgpezlvfl c61
27 May 22
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
4:48pm
424B5
ds3 tumw70juw
27 May 22
Prospectus supplement for primary offering
8:49am
8-K
o1ows6xipzhxw07q25y1
2 May 22
GeoVax Reports 2022 First Quarter Financial Results
7:30am
8-K
EX-99.1
e820us0rhdk1
2 May 22
GeoVax Reports 2022 First Quarter Financial Results
7:30am
8-K
EX-99.2
72850172gpg14euux
2 May 22
GeoVax Reports 2022 First Quarter Financial Results
7:30am